Shanghai Runda Medical Technology Co (603108) Fair Value & Analysis
Healthcare · CN · Market cap 6.4B CNY
Fair value as of: Aug 10, 2026
From 15 valuation models · updated today
Fair value updated Aug 10, 2026, revised from ¥5.71 to ¥5.70 (−0.2%) since Jul 11, 2026. Share price +18.0% over the past month.
Below-average quality, and screening another 46% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥8.98). The favourable scenario is already priced in.
- Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (¥2.42 to ¥8.98). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 10, 2026.
How to read this chart
60‑month range ¥8.71 – ¥26.34 · fair‑value band ¥2.42 – ¥8.98 · the ¥10.53 price screens above the ¥5.70 fair value. Dashed = 300-day average. As of Aug 10, 2026.
Analysis
Shanghai Runda Medical Technology Co (603108) currently trades at ¥10.53, while our model-based Fair Value estimate is ¥5.70, implying the stock looks roughly 45.9% overvalued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Shanghai Runda Medical Technology Co generated revenue of 6.8B CNY at a net margin of -7.8%. Revenue declined 9.1% year over year. It earns a return on equity of -9.7%. Net debt stands at 4.5B CNY. Fundamentals as of Aug 10, 2026
Our scenario range runs from ¥2.42 (bear case) to ¥8.98 (bull case); at ¥10.53, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 50% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -46%, 603108 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (¥16.06) versus Earnings-Based (¥2.41). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 10, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 40 · Market factors (momentum, volatility) 24
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai Runda Medical Technology Co., Ltd. provides medical laboratory services primarily in China. It offers laboratory design/renovation and SIMS stock information management system; medical solutions to help healthcare professionals; various customized laboratory management solutions; professional technical services; and logistic services.
Full company description
Shanghai Runda Medical Technology Co., Ltd. provides medical laboratory services primarily in China. It offers laboratory design/renovation and SIMS stock information management system; medical solutions to help healthcare professionals; various customized laboratory management solutions; professional technical services; and logistic services. The company also engages in the research and development, manufacturing, sale, and service of in vitro diagnostic products, including reagents and other consumables. In addition, it is involved in the software development; provision of information system integration and consulting services; sale of chemicals and medical devices; rental services; maintenance of electronic and mechanical equipment; import and export of technology; general cargo warehousing and road freight transportation; and wholesale of medicine. The company was incorporated in 1999 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Runda Medical Technology Co reported revenue of ¥7.0B in FY2025 versus ¥8.9B in FY2021, a compound −5.7%/yr. Reported net income was −¥548M in FY2025.
603108 screens 46% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 10, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare Shanghai Runda Medical Technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai Runda Medical Technology Co (603108) overvalued or undervalued?
What is the fair value of 603108?
What is the quality score of 603108?
What is the revenue of Shanghai Runda Medical Technology Co (603108)?
What is the net profit margin of 603108?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai Runda Medical Technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.